6.55
-0.14 (-2.02%)
| Penutupan Terdahulu | 6.68 |
| Buka | 6.81 |
| Jumlah Dagangan | 39,048 |
| Purata Dagangan (3B) | 54,943 |
| Modal Pasaran | 65,811,940 |
| Harga / Jualan (P/S) | 0.730 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Mar 2025 - 10 Mar 2025 |
| Margin Keuntungan | -41.16% |
| Margin Operasi (TTM) | -10.04% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.10% |
| Nisbah Semasa (MRQ) | 0.510 |
| Aliran Tunai Operasi (OCF TTM) | -35.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.07 M |
| Pulangan Atas Aset (ROA TTM) | -10.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | OptiNose, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.21% |
| % Dimiliki oleh Institusi | 78.44% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mvm Partners, Llc | 30 Sep 2024 | 973,733 |
| Great Point Partners I Lp | 30 Sep 2024 | 857,452 |
| Rosalind Advisors, Inc. | 30 Sep 2024 | 552,528 |
| Bleichroeder Lp | 30 Sep 2024 | 269,689 |
| Easterly Investment Partners Llc | 30 Sep 2024 | 157,290 |
| Velan Capital Investment Management Lp | 30 Sep 2024 | 143,114 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (HC Wainwright & Co., 175.02%) | Beli |
| Median | 9.50 (45.15%) | |
| Rendah | 1.00 (Piper Sandler, -84.72%) | Beli |
| Purata | 9.50 (45.15%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 7.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Jan 2025 | 18.00 (175.02%) | Beli | 6.54 |
| 13 Nov 2024 | 5.00 (-23.61%) | Beli | 7.61 | |
| Piper Sandler | 13 Nov 2024 | 1.00 (-84.72%) | Beli | 7.61 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Dec 2024 | Pengumuman | Optinose Announces 1-for-15 Reverse Stock Split |
| 02 Dec 2024 | Pengumuman | Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference |
| 12 Nov 2024 | Pengumuman | Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights |
| 05 Nov 2024 | Pengumuman | Optinose Announces Reporting Date for Third Quarter 2024 Financial Results |
| 16 Oct 2024 | Pengumuman | Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Oct 2024 | Pengumuman | Optinose Appoints Terry Kohler as Chief Financial Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |